知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.018 seconds)

    TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS
    3.
    发明申请
    TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS 审中-公开
    在动物中治疗代谢性疾病

    公开(公告)号：US20150164856A1

    公开(公告)日：2015-06-18

    申请号：US14573352

    申请日：2014-12-17

    Applicant: Boehringer Ingelheim Vetmedica GmbH

    Inventor： Dania Birte REICHE ,  Silke HAAG-DIERGARTEN ,  Leah Jeanette HENNINGS ,  Saskia KLEY ,  Anne M. TRAAS

    IPC: A61K31/351 ,  A61K38/28

    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

    Abstract translation: 本发明涉及用于治疗和/或预防猫科动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式，优选其中代谢紊乱是选自以下的一种或多种：酮症酸中毒 ，前期糖尿病，1型糖尿病或2型糖尿病，胰岛素抵抗，肥胖症，高血糖症，葡萄糖耐量降低，高胰岛素血症，血脂异常，血管兴奋素血症，亚临床炎症，全身炎症，低度全身炎症，肝脂质变性，动脉粥样硬化，胰腺炎症 ，神经病和/或综合征X（代谢综合征）和/或胰腺β细胞功能丧失和/或其中代谢紊乱的缓解，优选糖尿病缓解获得和/或维持。

    TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS
    9.
    发明申请
    TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS 审中-公开

    公开(公告)号：US20200179328A1

    公开(公告)日：2020-06-11

    申请号：US16790810

    申请日：2020-02-14

    Applicant: Boehringer Ingelheim Vetmedica GmbH

    Inventor： Saskia KLEY ,  Dania REICHE

    IPC: A61K31/351 ,  A61K31/401 ,  A61K9/48 ,  A61K9/20 ,  A61K9/00 ,  A61K38/28 ,  A61K31/00 ,  A61K9/08 ,  A61K45/06 ,  A61K31/7034 ,  A61K9/02 ,  C07D309/10

    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.

    TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS
    10.
    发明申请
    TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS 审中-公开
    治疗犬动物代谢障碍

    公开(公告)号：US20160361289A1

    公开(公告)日：2016-12-15

    申请号：US15113127

    申请日：2015-01-20

    Applicant: Boehringer Ingelheim Vetmedica GmbH

    Inventor： Saskia KLEY ,  Dania Birte REICHE

    IPC: A61K31/351 ,  A61K9/48 ,  A61K38/28 ,  A61K9/20 ,  A61K31/401 ,  A61K9/00

    CPC classification number: A61K31/351 ,  A61K9/0053 ,  A61K9/02 ,  A61K9/08 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/00 ,  A61K31/401 ,  A61K31/7034 ,  A61K38/28 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or muscoskeletal disorders, is prevented or progression is slowed or remission is achieved.

    Abstract translation: 本发明涉及用于治疗和/或预防犬动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式，优选其中所述代谢病症是选自以下的一种或多种：酮症酸中毒 ，糖尿病前期，胰岛素依赖性糖尿病，胰岛素抵抗糖尿病，胰岛素抵抗，肥胖症，高血糖症，高血糖诱导的白内障形成，葡萄糖耐量降低，高胰岛素血症，血脂异常，血管兴奋素血症，亚临床炎症，全身炎症，低度全身炎症，肝脂质沉积， 胰腺炎症，代谢紊乱后果如高血压，肾功能障碍和/或肌肉骨骼疾病和/或综合征X（代谢综合征），其中优选地，预防或发展高血糖诱导的白内障形成的发展和/或其中 最好是代谢紊乱的发展 如高血压，肾功能障碍和/或肌肉骨骼疾病等后遗症被阻止或进展缓慢或达到缓解。

Patent Agency Ranking